-
公开(公告)号:US20070225316A1
公开(公告)日:2007-09-27
申请号:US11698318
申请日:2007-01-25
IPC分类号: A61K31/4745
CPC分类号: A61K31/437 , A61K31/444
摘要: The present invention relates to methods and compositions useful for treating, preventing and/or delaying the onset and/or development of schizophrenia by administering a hydrogenated pyrido[4,3-b]indole, such as dimebon, or a pharmaceutically acceptable salt thereof, to an individual.
摘要翻译: 本发明涉及用于治疗,预防和/或延迟精神分裂症的发作和/或发展的方法和组合物,其通过施用氢化吡啶并[4,3-b]吲哚(例如二甲基)或其药学上可接受的盐, 给个人
-
公开(公告)号:US20070179174A1
公开(公告)日:2007-08-02
申请号:US11644698
申请日:2006-12-22
IPC分类号: A61K31/4745
CPC分类号: A61K31/4745
摘要: The present invention provides a pharmacological agent based on derivatives of hydrogenated pyrido (4,3-b) indoles and uses thereof. Specifically, the invention provides a geroprotector in the series of hydrogenated pyrido (4,3-b) indoles (several derivatives), which can be used for slowing aging, prolonging lifespan of an individual or cells in an individual, and/or improving quality of life of an individual developing or having a risk of developing age-associated manifestations and/or pathologies.
摘要翻译: 本发明提供了一种基于氢化吡啶并(4,3-b)吲哚衍生物的药理学及其应用。 具体地说,本发明提供了一系列氢化吡啶并(4,3-b)吲哚(几种衍生物)中的保护剂,其可用于减缓老化,延长个体或个体中的细胞的寿命和/或提高质量 的发展中国家或有发展年龄相关表现和/或病态风险的个体的生命。
-
公开(公告)号:US20050096342A1
公开(公告)日:2005-05-05
申请号:US11004001
申请日:2004-12-02
申请人: Nikolai Zefirov , Andrei Afanasiev , Svetlana Afanasieva , Sergei Bachurin , Sergei Tkachenko , Vladimir Grigoriev , Marina Jurovskaya , Valery Chetverikov , Elizaveta Bukatina , Irina Grigorieva
发明人: Nikolai Zefirov , Andrei Afanasiev , Svetlana Afanasieva , Sergei Bachurin , Sergei Tkachenko , Vladimir Grigoriev , Marina Jurovskaya , Valery Chetverikov , Elizaveta Bukatina , Irina Grigorieva
IPC分类号: A61K31/437 , A61P25/28 , A61K31/4745
CPC分类号: A61K49/006 , A61K31/437
摘要: Compounds and methods of using these compounds to treat neurodegenerative diseases, especially Alzheimer's disease, are provided. The compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I): wherein R1 is Me, Et or PhCH2; R2 is H, PhCH2 or 6-Me-3-Py-(CH2)2; and R3 is H, Me or Br. The solid line accompanied by the dotted line i.e. represents a single or double bond and salts thereof with pharmacologically acceptable acids and quaternary derivatives.
摘要翻译: 提供了使用这些化合物治疗神经变性疾病,特别是阿尔茨海默氏病的化合物和方法。 提供用于治疗神经变性疾病的化合物可以由通式(I)表示:其中R 1是Me,Et或PhCH 2; R 2是H,PhCH 2或6-Me-3-Py-(CH 2 2)2。 R 3是H,Me或Br。 伴随着虚线的实线即代表单键或双键,其盐与药理学上可接受的酸和季衍生物。
-
公开(公告)号:US20060140866A1
公开(公告)日:2006-06-29
申请号:US11361628
申请日:2006-02-24
申请人: Nikolai Zefirov , Andrei Afanasiev , Svetlana Afanasieva , Sergei Bachurin , Sergei Tkachenko , Vladimir Grigoriev , Marina Jurovskaya , Valery Chetverikov , Elizaveta Bukatina , Irina Grigorieva
发明人: Nikolai Zefirov , Andrei Afanasiev , Svetlana Afanasieva , Sergei Bachurin , Sergei Tkachenko , Vladimir Grigoriev , Marina Jurovskaya , Valery Chetverikov , Elizaveta Bukatina , Irina Grigorieva
IPC分类号: A61K49/00
CPC分类号: A61K49/006 , A61K31/437
摘要: Compounds and methods of using these compounds to treat neurodegenerative diseases, especially Alzheimer's disease, are provided. The compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I): wherein R1 is Me, Et or PhCH2; R2 is H, PhCH2 or 6-Me-3-Py-(CH2)2; and R3 is H, Me or Br. The solid line accompanied by the dotted line i.e. represents a single or double bond and salts thereof with pharmacologically acceptable acids and quaternary derivatives.
摘要翻译: 提供了使用这些化合物治疗神经变性疾病,特别是阿尔茨海默氏病的化合物和方法。 提供用于治疗神经变性疾病的化合物可以由通式(I)表示:其中R 1是Me,Et或PhCH 2; R 2是H,PhCH 2或6-Me-3-Py-(CH 2 2)2。 R 3是H,Me或Br。 虚线中的实线 ie表示单键或双键及其盐与药理学上可接受的酸和季衍生物。
-
-
-